NEVRO CORP. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-11-25: Reporting owner Galligan Andrew H; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-11-11: Reporting owner Galligan Andrew H; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-11-11: Reporting owner Galligan Andrew H; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-07-16: Reporting owner Galligan Andrew H; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-11-25 | Galligan Andrew H Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,000 20,500 owned after | $63.23 exercise price | 2019-11-26 | |
| 2019-11-11 | Galligan Andrew H Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,522 14,941 owned after | $18.00 exercise price | 2019-11-13 | |
| 2019-11-11 | Galligan Andrew H Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,000 32,500 owned after | $63.23 exercise price | 2019-11-13 | |
| 2019-07-16 | Galligan Andrew H Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 41,394 owned after | $3.60 exercise price | 2019-07-17 | |
| 2019-07-15 | Pellegrini Niamh Louise Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +71,575 71,575 owned after | $64.95 exercise price | 2019-07-17 | |
| 2019-03-05 | Alleavitch Doug Officer (VP, Quality) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,031 15,469 owned after | $42.30 exercise price | 2019-03-07 | |
| 2019-02-20 | Carter Michael Collier Officer (Vice President, Sales) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +78,700 78,700 owned after | $48.44 exercise price | 2019-02-22 | |
| 2019-01-04 | Galligan Andrew H Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,004 0 owned after | $1.44 exercise price | 2019-01-08 |